Related Experiment Videos
Alveolar soft-part sarcoma responsive to intensive chemotherapy.
H James Nickerson1, Teresa Silberman, F Stig Jacobsen
1Department of Pediatrics, Marshfield Clinic, WI 54449, USA. nickerson.harlan@marshfieldclinic.org
Journal of Pediatric Hematology/Oncology
|April 17, 2004
Summary
Alveolar soft-part sarcoma (ASPS), a rare cancer, typically affects young adults. Intensive chemotherapy effectively treated pulmonary metastases in a 13-year-old, leading to a 10-year disease-free survival.
Area of Science:
- Oncology
- Pediatric Oncology
- Sarcoma Research
Background:
- Alveolar soft-part sarcoma (ASPS) is a rare malignancy predominantly affecting adolescents and young adults, often presenting in the extremities.
- Current treatment paradigms suggest limited efficacy of adjuvant radiation and chemotherapy for ASPS, with surgical excision being the primary modality for prolonged survival.
- The rarity and aggressive nature of ASPS, particularly with metastatic disease at diagnosis, pose significant therapeutic challenges.
Observation:
- A 13-year-old patient was diagnosed with ASPS of an extremity accompanied by multiple bilateral pulmonary metastases.
- The patient received intensive multiagent chemotherapy as a primary treatment modality for the metastatic disease.
- Initial response assessment revealed in vivo evidence of tumor death within the pulmonary metastases.
Findings:
- Intensive multiagent chemotherapy demonstrated significant efficacy in treating pulmonary metastases of alveolar soft-part sarcoma.
- The patient achieved a sustained 10-year disease-free survival following the chemotherapy regimen.
- This case challenges the conventional view of chemotherapy's ineffectiveness in advanced ASPS.
Implications:
- Aggressive multiagent chemotherapy may represent a viable and effective treatment option for pediatric patients with metastatic alveolar soft-part sarcoma.
- This case highlights the potential for long-term remission in ASPS with appropriate systemic therapy, even in the presence of extensive metastases.
- Further research into the specific chemotherapeutic agents and regimens effective in ASPS is warranted to optimize treatment strategies for this rare sarcoma.